Cannabidiol Oral Solution ( DrugBank: Cannabidiol )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
140	ドラベ症候群	2
144	レノックス・ガストー症候群	3
145	ウエスト症候群	1
193	プラダー・ウィリ症候群	5

140. ドラベ症候群

臨床試験数 : 116 / 薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04485104 (ClinicalTrials.gov)	May 19, 2021	21/7/2020	Assessment of Adjunctive Cannabidiol Oral Solution(GWP42003-P) in Children With Tuberous Sclerosis C ...	An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive C ...	Seizure in Participants With Tuberous Sclerosis Complex;Seizure in Participants With Dravet Syndrome ...	Drug: GWP42003-P	Jazz Pharmaceuticals	NULL	Recruiting	1 Month	23 Months	All	27	Phase 3	United States
2	NCT02318563 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	Cannabidiol Oral Solutionas an Adjunctive Therapy for Treatment of Participants With Inadequately Co ...	A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Saf ...	Dravet Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	1 Year	30 Years	All	0	Phase 3	NULL

First Previous1Next Last

144. レノックス・ガストー症候群

臨床試験数 : 111 / 薬物数 : 72 - (DrugBank : 14) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 61

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04485104 (ClinicalTrials.gov)	May 19, 2021	21/7/2020	Assessment of Adjunctive Cannabidiol Oral Solution(GWP42003-P) in Children With Tuberous Sclerosis C ...	An Open-label, Single-arm Study to Assess the Safety, Pharmacokinetics, and Efficacy of Adjunctive C ...	Seizure in Participants With Tuberous Sclerosis Complex;Seizure in Participants With Dravet Syndrome ...	Drug: GWP42003-P	Jazz Pharmaceuticals	NULL	Recruiting	1 Month	23 Months	All	27	Phase 3	United States
2	NCT04133480 (ClinicalTrials.gov)	October 2020	17/10/2019	Investigation of Cognitive Outcomes With Cannabidiol Oral Solution	An Open-Label Exploratory Investigation of Cognitive Outcomes With Cannabidiol Oral Solution(EPIDIOL ...	Lennox-Gastaut Syndrome	Drug: GWP42003-P	Jazz Pharmaceuticals	NULL	Withdrawn	3 Years	10 Years	All	0	Phase 4	United States
3	NCT02318537 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	Cannabidiol Oral Solutionas an Adjunctive Therapy for Treatment of Participants With Inadequately Co ...	A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safe ...	Lennox-Gastaut Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	2 Years	30 Years	All	0	Phase 3	NULL

First Previous1Next Last

145. ウエスト症候群

臨床試験数 : 43 / 薬物数 : 52 - (DrugBank : 15) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 26

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03421496 (ClinicalTrials.gov)	September 5, 2018	26/1/2018	A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral SolutionWith Vigabatrin ...	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, ...	Infantile Spasm	Drug: Cannabidiol Oral Solution;Drug: Placebo;Drug: Vigabatrin	Benuvia Therapeutics Inc.	NULL	Terminated	1 Month	24 Months	All	2	Phase 3	United States

First Previous1Next Last

193. プラダー・ウィリ症候群

臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05387798 (ClinicalTrials.gov)	January 2023	17/5/2022	A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndro ...	A Phase 3, Open-label Extension Study to Assess the Safety, Tolerability, and Efficacy of RAD011 (Ca ...	Prader-Willi Syndrome	Drug: RAD011	Radius Pharmaceuticals, Inc.	NULL	Withdrawn	8 Years	65 Years	All	0	Phase 3	NULL
2	NCT05098509 (ClinicalTrials.gov)	April 13, 2022	22/9/2021	A Phase 2/3 Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients With Prader-Wi ...	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution ...	Prader-Willi Syndrome	Drug: RAD011;Drug: Placebo	Radius Pharmaceuticals, Inc.	NULL	Terminated	8 Years	65 Years	All	7	Phase 2/Phase 3	United States
3	NCT03458416 (ClinicalTrials.gov)	September 6, 2018	2/3/2018	A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solutionin ...	A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Can ...	Prader-Willi Syndrome	Drug: Cannabidiol Oral Solution	Benuvia Therapeutics Inc.	NULL	Terminated	8 Years	17 Years	All	7	Phase 2	United States
4	NCT02844933 (ClinicalTrials.gov)	June 6, 2018	22/7/2016	Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome	A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and To ...	Prader-Willi Syndrome	Drug: Cannabidiol;Drug: Placebo	Benuvia Therapeutics Inc.	NULL	Terminated	8 Years	17 Years	All	7	Phase 2	United States
5	EUCTR2021-005331-23-SE (EUCTR)		18/05/2022	A Study of RAD011 (Cannabidiol Oral Solution) for the Treatment of Patients with Prader-Willi Syndro ...	A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of RAD011 (Cannabidiol Oral Solution ...	Hyperphagia related behavior associated with Prader-Willi Syndrome MedDRA version: 20.0;Level: PT;Cl ...	Product Name: RAD011 Product Code: RAD011 INN or Proposed INN: Cannabidiol	Radius Pharmaceuticals, Inc.	NULL	Not Recruiting			Female: yes Male: yes	220	Phase 2;Phase 3	France;United States;Canada;Belgium;Spain;Australia;United Kingdom;Italy;Sweden

First Previous1Next Last

先頭へ